ARGX catalyst calendar

ARGENX SE

Upcoming catalysts
30
Cash runway
Cash generating
Cash & investments
$3491M
Phase 3 programs
32

ARGENX SE is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis on November 15, 2026. There are 30 upcoming events on record.

ARGENX SE generates cash from operations, so a burn-based runway figure does not apply.

Across 43 concluded trials, 81% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 15, 2026 A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis Trial Milestone Phase 2
December 15, 2026 A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants Trial Milestone Phase 1
December 31, 2026 A Study to Assess the Safety of ARGX-124 in Healthy Volunteers Trial Milestone Phase 1
February 15, 2027 A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis Trial Milestone Phase 2
March 15, 2027 Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Trial Milestone Phase 2/Phase 3
March 15, 2027 A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants Trial Milestone Phase 1
April 30, 2027 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Trial Milestone Phase 2
July 15, 2027 A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome Trial Milestone Phase 3
August 24, 2027 A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) Trial Milestone Phase 1
September 15, 2027 A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis Trial Milestone Phase 2/Phase 3
September 15, 2027 A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP Trial Milestone Phase 3
October 7, 2027 A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Trial Milestone Phase 3
October 15, 2027 ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis Trial Milestone Phase 2
November 15, 2027 A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) Trial Milestone Phase 2
January 15, 2028 A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome Trial Milestone Phase 2
February 1, 2028 A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy Trial Milestone Phase 1
March 7, 2028 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod Trial Milestone Phase 2
April 15, 2028 A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Trial Milestone Phase 2/Phase 3
June 15, 2028 A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Trial Milestone Phase 3
June 15, 2028 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Trial Milestone Phase 3
June 15, 2028 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease. Trial Milestone Phase 3
July 28, 2028 A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) Trial Milestone Phase 2
September 15, 2028 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Trial Milestone Phase 3
October 15, 2028 A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Trial Milestone Phase 2/Phase 3
May 28, 2029 A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy Trial Milestone Phase 2
September 15, 2029 Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis Trial Milestone Phase 2/Phase 3
September 30, 2029 A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy Trial Milestone Phase 2
October 29, 2029 A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN Trial Milestone Phase 2
July 15, 2030 A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults Trial Milestone Phase 2
October 15, 2030 A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) Trial Milestone Phase 3

Track ARGX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open ARGX in the tracker

Recent history

DateEventTypePhase
October 8, 2026 6-K filed: Foreign issuer report Filing —
October 1, 2026 A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Trial Milestone Phase 3
September 29, 2026 6-K filed: Foreign issuer report Filing —
September 23, 2026 A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants Trial Milestone Phase 1
September 15, 2026 A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy Trial Milestone Phase 3
August 27, 2026 6-K filed: Foreign issuer report Filing —
August 17, 2026 6-K filed: Foreign issuer report Filing —
August 15, 2026 A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) Trial Milestone Phase 4
August 12, 2026 A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) Trial Milestone Phase 2
August 3, 2026 6-K filed: Foreign issuer report Filing —
July 27, 2026 6-K filed: Foreign issuer report Filing —
July 23, 2026 6-K filed: Foreign issuer report Filing —
July 2, 2026 A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Trial Milestone Phase 2/Phase 3
June 23, 2026 6-K filed: Foreign issuer report Filing —
June 3, 2026 6-K filed: Foreign issuer report Filing —
May 11, 2026 6-K filed: Foreign issuer report Filing —
May 7, 2026 6-K filed: Foreign issuer report Filing —
May 6, 2026 6-K filed: Foreign issuer report Filing —
April 20, 2026 6-K filed: Foreign issuer report Filing —
March 20, 2026 6-K filed: Foreign issuer report Filing —
March 20, 2026 A Study to Assess the Safety of ARGX-213 in Healthy Volunteers Trial Milestone Phase 1
March 19, 2026 6-K filed: Foreign issuer report Filing —
March 19, 2026 Results filed (20-F) Earnings —
March 11, 2026 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Trial Milestone Phase 3
March 6, 2026 6-K filed: Foreign issuer report Filing —
February 26, 2026 6-K filed: Foreign issuer report Filing —
February 26, 2026 6-K filed: Foreign issuer report Filing —
February 19, 2026 A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC Trial Milestone Phase 4
January 13, 2026 6-K filed: Foreign issuer report Filing —
January 12, 2026 6-K filed: Foreign issuer report Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.